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Abstract 14 
 15 
Background: Uganda changed its antiretroviral therapy guidelines in 2014, increasing the CD4 16 
threshold for antiretroviral therapy initiation from 350 cells/µl to 500 cells/µl. We investigate what 17 
effect this change in policy is likely to have on HIV incidence, morbidity, and programme costs, and 18 
estimate the cost-effectiveness of the change over different time horizons. 19 
Methods: We used a complex individual-based model of HIV transmission and antiretroviral therapy 20 
scale-up in Uganda. 100 model fits were generated by fitting the model to 51 demographic, sexual 21 
behaviour, and epidemiological calibration targets, varying 96 input parameters, using history 22 
matching with model emulation. An additional 19 cost and disability weight parameters were varied 23 
during the analysis of the model results. For each model fit, the model was run to 2030, with and 24 
without the change in threshold to 500 cells/µl. 25 
Results: The change in threshold led to a 9.7% (90% plausible range: 4.3%-15.0%) reduction in 26 
incidence in 2030, and averted 278,944 (118,452-502,790) DALYs, at a total cost of $28M (-$142M to 27 
+$195M). The cost per disability adjusted life year (DALY) averted fell over time, from $3238 (-$125 28 
to +$29,969) in 2014 to $100 (-$499 to +$785) in 2030. The change in threshold was cost-effective 29 
(cost <3×Uganda’s per capita GDP per DALY averted) by 2018, and highly cost-effective (cost 30 
<Uganda’s per capita GDP per DALY averted) by 2022, for more than 50% of parameter sets. 31 
Conclusions: Model results suggest that the change in threshold is unlikely to have been cost-32 
effective to date, but is likely to be highly cost-effective in Uganda by 2030. The time horizon needs 33 
to be chosen carefully when projecting intervention effects. Large amounts of uncertainty in our 34 
results demonstrates the need to comprehensively incorporate uncertainties in model 35 
parameterisation. 36 
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Introduction 37 
The World Health Organization (WHO) published its first guidelines for antiretroviral therapy (ART) 38 
provision in resource limited settings in 2002, at which time it recommended that ART be provided 39 
for all people living with HIV with CD4 counts of <200 cells/µl[1]. Since then, WHO’s recommended 40 
threshold for initiating ART has increased over time, reaching <500 cells/µl in 2013[2]. From 41 
September 2015, WHO has recommended universal access to ART for all people living with HIV[3].  42 
ART first became freely available through the Ministry of Health in Uganda in 2003, with local 43 
guidelines recommending ART initiation at CD4 counts of <200 cells/µl[4]. This threshold was 44 
increased gradually over time, to 250 cells/μl in 2009, 350 cells/μl in 2010, and 500 cells/μl in 45 
2014[5]. 46 
Mathematical modelling provides one way of estimating the costs and effects of changes in ART 47 
guidelines. Previous studies have investigated the cost-effectiveness of changes in guidelines in a 48 
number of different sub-Saharan African countries and settings, including South Africa[6-8], Eastern 49 
Africa[9], and Zambia[10]. In this study, we use mathematical modelling to investigate what effect 50 
Uganda’s 2014 change in policy (from ART at CD4 counts <350 cells/µl to <500 cells/µl) is likely to 51 
have on HIV incidence, morbidity, and mortality. We also estimate programme costs, and the cost-52 
effectiveness of the change over time. We provide a comprehensive measure of the level of 53 
uncertainty in all our results. 54 
 55 
Methods 56 
Model description 57 
This study was conducted using an individual-based model of HIV transmission and care, described in 58 
full in Appendices S1 and S2, reproduced from McCreesh et al 2016[11]. The model simulates 59 
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population demography (births, deaths, and population growth), sexual behaviour (the formation 60 
and dissolution of monogamous and concurrent sexual partnerships), HIV transmission, and HIV 61 
care. Simulated HIV positive people can be not in care, in pre-ART care, on ART, or dropped out of 62 
ART. Movement into care (pre-ART care or on ART) occurs following a positive HIV test and 63 
successful linkage to care. People can start ART from pre-ART care or directly following a positive HIV 64 
test if they have a CD4 test that indicates that they are below the threshold for ART initiation, if they 65 
experience severe morbidity, or if they are pregnant and an Option B+ policy is in place. Receiving 66 
ART in the model reduces and individual’s mortality rates, and the probability that they will transmit 67 
HIV to their sexual partners. 68 
 69 
ART scale-up and coverage 70 
The model introduces ART in 2003, the year when ART first became freely available in Uganda 71 
through Ministry of Health programs[4]. Changes to ART eligibility criteria between 2003 and 2014 72 
were simulated in the model. From 2003-2008, ART was available only to people with CD4 counts 73 
below 200 cells/μl, or with WHO stage 3 or 4 conditions. The CD4 threshold for ART initiation 74 
increased progressively over time, to 250 cells/μl in 2009, 350 cells/μl in 2010, and to 500 cells/μl in 75 
2014[5]. In addition to this, Option B+, which makes all pregnant women eligible for lifetime ART, 76 
was adopted throughout the country by the start of 2014. The model immediately fully implements 77 
the change in threshold from 200 to 250 cells/μl at the start of 2009. The other changes in threshold 78 
were implemented more slowly in the model, with a proportion of people assumed to seek/obtain 79 
treatment at a clinic where the new guidelines were immediately implemented, and the remaining 80 
people seeking treatment at a clinic where the guidelines were adopted after a delay of two years. 81 
The proportion of people seeking treatments at clinics that immediately adopted new guidelines was 82 
controlled by an input parameter that was allowed to vary during model fitting. The plausible range 83 
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for this parameter was set to 0-1. Option B+ was fully implemented in the model from the start of 84 
2014. 85 
In addition to changes in the ART eligibility criteria, a number of step changes in model parameter 86 
values were simulated in various model years. These reflected increases in access to treatment in 87 
Uganda, and were necessary to allow the model to fit the empirical ART coverage and initiation data. 88 
Step changes in HIV testing rates were modelled in 2005, 2007, and 2012, to allow the model to fit 89 
to data on HIV testing coverage over time. Additional step changes in model parameter values in 90 
2008 and 2012 allowed the probability of linking to care following a positive HIV test, the probability 91 
of immediately starting ART after testing positive when below the CD4 threshold, and the probability 92 
of starting ART following a stage 3 or 4 clinical event to increase over time. 93 
 94 
Model fitting 95 
The model was fitted to routinely collected, countrywide data on the proportion of HIV positive 96 
adults (aged 15-49 years) receiving ART in 2005, 2007, 2009, 2011, and 2013, and the proportion of 97 
people newly starting ART with a CD4 count of less than 250 cells/µl in the same years[12, 13]. The 98 
model was also fitted to data on the proportion of people newly starting ART in 2010 who were 99 
women, and the increase in this proportion between 2010 and 2014[12, 14], to capture the effects 100 
of the introduction of Option B+. Other fitted outputs included: 101 
 Overall adult (15-49 year old) HIV prevalence in 1991, and adult HIV prevalence by gender in 102 
2004 and 2011[15]. 103 
 Rates of dropping out of and restarting ART[16], and 12-month retention on ART[12]. 104 
 The proportion of people receiving ART who were on 2nd line treatment in 2010 and 105 
2014[12, 14]. 106 
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 The proportion of men and women who had ever been tested for HIV in 2004 and 2006, and 107 
the proportion of HIV- and HIV+ men and women who had ever been tested for HIV in 108 
2011[17]. 109 
 The estimated adult (15-49 year-old) male and female population size in Uganda in 2015, 110 
and the growth in population size between 1950-2015[18]. 111 
 The incidence and prevalence of monogamous and concurrent sexual partnerships in 2015, 112 
based on data from a rural population cohort in South-West Uganda[19-21]. 113 
In total, 51 outputs were fitted, and 96 inputs were allowed to vary during the fitting process, 114 
incorporating a large number of the potential sources of uncertainty in the correct values of model 115 
parameters and output targets. These included the effects of ART on mortality and on HIV 116 
transmission. The model was calibrated using history matching with model emulation, which 117 
iteratively rejects areas of space where model fits are unlikely to be found[22, 23]. Using this 118 
approach, we generated a total of 100 model fits (input parameter combinations) which were 119 
consistent with empirical data. Full details of the fitting method are given in McCreesh et al[11, 24] 120 
and Andrianakis et al[25]. 121 
 122 
Model scenarios 123 
Two scenarios were simulated. In the first, we simulated ART scale-up in Uganda as it occurred, 124 
including the change in guidelines in 2014 which increased the CD4 threshold at which people 125 
became eligible for ART from 350 cells/µl to 500 cells/µl. For the second, we simulated a scenario 126 
where Uganda did not adopt a CD4 threshold for ART initiation of 500 cells/µl in 2014 and instead 127 
retained the 350 cells/µl threshold from 2010. 128 
The model was run for each of the 100 model fits for both scenarios. As the model is stochastic, 129 
results were averaged for multiple repetitions (2000) for each fit and scenario. 130 
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Costs and disability adjusted life years (DALYs) averted 131 
Fifteen cost parameters were used to calculate the overall costs to the healthcare system in each 132 
scenario. These included programme costs for pre-ART and ART care, 1st and 2nd line drug costs, HIV 133 
and CD4 test costs, and healthcare costs arising from HIV-associated morbidity. Costs were 134 
considered uncertain, and published data sources were used to determine a plausible range for each 135 
cost parameter. Costs are in 2015 USD. For full details, see McCreesh et al[11]. 136 
Four DALY parameters were used to estimate the effects of adopting the higher CD4 threshold on 137 
DALYs averted. These parameters determined the relationship between CD4 count and morbidity, 138 
the reduction in morbidity while in pre-ART care, the reduction in morbidity during the first six 139 
months on ART, and the disability weight while on established ART. Plausible ranges for disability 140 
weights were based on 95% confidence intervals from the Global Burden of Disease Study 2010[26], 141 
and data on reductions in rates of hospitalisations after starting cotrimoxazole prophylaxis[27]. 142 
DALYs were not age-weighted. Full details are given in McCreesh et al[11]. 143 
Latin hypercube sampling was used to select 2000 sets of values for the cost and DALY parameters, 144 
sampling uniform distributions over their plausible ranges. These were combined with the 100 145 
model fits to obtain 2000 parameter sets, with each model fit being combined with 20 different 146 
cost/DALY sets. For each parameter set, the additional costs and DALYs averted that resulted from 147 
implementing the higher CD4 threshold were calculated. The net monetary benefit (NMB) of the 148 
threshold change was also calculated for each parameter set for a wide range of different values of 149 
willingness to pay per DALY averted (WTP, $0-$2500), using the formula NMB = DALYs averted x WTP 150 
– cost. All costs and DALYs were discounted by 3% per year in the main analysis. In addition, a 151 
sensitivity analysis was conducted to explore the effect of the choice of discount rates. 152 
 153 
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Results 154 
Fit to data 155 
The model fitted closely to the plausible ranges for all 51 outputs. Figure 1 shows the model fit to 156 
the key ART scale-up outputs, as well as the HIV prevalence over time, and ART dropout and restart 157 
rates. Fits to the remaining outputs are given in McCreesh et al[11]. 158 
 159 
Figure 1. Model baseline fit to empirical data. Graphs a-g: Black dots show the empirical estimates, and the 160 
error bars show the plausible ranges for the output values. Black lines show the median model output. 161 
Blue/green bands show 10% quantiles of model outputs, from the 100 model fits. The full width of the band 162 
shows the range of the model output. Graphs h-i: Orange boxes show the empirical data and plausible ranges. 163 
Green boxes show the model output. Model fits to the remaining 20 outcomes are show in McCreesh et al[11] 164 
 165 
Costs, benefits, and cost-effectiveness 166 
In the model, increasing the CD4 threshold for ART initiation increased annual costs by a maximum 167 
of $10 million (90% plausible range: -$89,526 to +$26 million) in 2016 (2014-2017) (Figure 2d). 168 
Cumulative costs increased over time to a maximum of 47 million USD (90% plausible range: -169 
$89,526 to +$196 million) in 2023 (2014-2030), before falling to 28 million USD (-$142 million +$195 170 
million) in 2030 (Figure 2a). The change in threshold was cost saving by 2030 in 39% of parameter 171 
sets. 172 
Figure 2. Costs and effects over time of the change in CD4 threshold. a) Total additional costs over time 173 
(cumulative). b) Total DALYs averted over time (cumulative) (bands) and proportion of parameter sets where 174 
the number of DALYS averted was negative (dashed line, second axis). c) Total cost per DALY averted over time 175 
(parameter sets are excluded if the cumulative number of DALYs averted by that year are negative). d) Annual 176 
additional costs over time. e) Annual DALYs averted over time (cumulative) (bands) and proportion of 177 
parameter sets where the number of DALYS averted was negative (dashed line, second axis). f) Annual cost per 178 
9 
 
DALY averted over time (parameter sets are excluded if the number of DALYs averted in that year are negative). 179 
g) Reduction in annual HIV incidence with the change in CD4 threshold, compared to scenario with no change. 180 
h) Reduction in annual HIV mortality rates with the change in CD4 threshold, compared to scenario with no 181 
change. Black lines show the median model output, and blue/green bands show 10% quantiles of model 182 
outputs, from the 2000 parameter sets. 183 
Increasing the CD4 threshold for ART initiation averted a total of 278,944 (90% plausible range: 184 
118,452-502,790) DALYs by 2030 (Figure 2b). In contrast to the reductions in HIV incidence, the rate 185 
at which DALYs were averted increased over time, with over half the DALYs averted being averted 186 
during the five years from 2026 to 2030, and the highest number of DALYs being averted in 2030 187 
(35,084 (15,129 to 66,965), Figure 2e). The very small effect of the change in threshold on DALYs 188 
averted in the years immediately following the introduction of the new threshold, combined with 189 
the stochastic nature of the model, meant that for some parameter sets the overall number of 190 
DALYs averted was negative during the first few years of the intervention. This fell rapidly from 31% 191 
of parameter sets in 2014, to <1% by 2019. 192 
The total cost per DALY averted fell over time, from a maximum of $3238 (90% plausible range: -193 
$125 to +$29,969) during the first year after the introduction of the change in threshold, to a 194 
minimum of $100 (-$499 to +$785) in 2030 (Figure 2c). The annual cost per DALY averted fell from 195 
$3238 (-$125 to +$29,969) in 2014 to -$114 (-$408 to +$159) in 2030 (Figure 2f). The cost per DALY 196 
averted increased slightly between 2015 and 2016, as the change in threshold was assumed to be 197 
fully implemented in all clinics in 2016. Figure 3 shows the probability that the change in threshold 198 
was cost-effective, by year and willingness to pay per DALY averted (WTP). During the first year after 199 
implementation, it was highly unlikely that the intervention was cost-effective (had a positive net 200 
benefit), even at a high WTP of $2500 per DALY averted. By 2030, the intervention was cost-effective 201 
for more than 50% of parameter sets at a WTP of $100, 14% of Uganda’s per capita GDP. The World 202 
Health Organization (WHO) considers interventions to be cost-effective if they cost less than three 203 
times a country’s per capita GDP per DALY averted, and highly cost-effective if they cost less than 204 
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one times a country’s per capita GDP per DALY averted. Using these WTP values, for more than 50% 205 
of parameter sets, the change in threshold was cost-effective by 2018, and highly cost-effective by 206 
2022. 207 
Figure 3. Probability that the change in CD4 threshold is cost-effective, by time horizon and willingness to 208 
pay per DALY averted. Black lines indicate where 25%, 50%, 75%, and 100% of parameter sets are cost-209 
effective. Horizontal dashed lines indicate one and three times Uganda’s per capita GDP. 210 
Our results were relatively insensitive to the choice of discount rates, with the cost per DALY averted 211 
in 2030 ranging from $62 ($-487 to +$666) with no discounting, to $143 ($-513 to +$901) with costs 212 
and DALYs discounted by 6% per year (Table 1). Using WHO criteria, with all discount rates we 213 
considered, the intervention first became cost-effective in 2018, and highly cost-effective in 2022-214 
2023. 215 
Discount rates (per 
year) 
 Year in which, for >50% of parameter sets, the 
intervention first becomes: 
Costs DALYs Cost per DALY 
averted in 2030 (90% 
CI) 
Cost effective 
(cost/DALY averted 
<3×Uganda per capita 
GDP) 
Highly cost-effective 
(cost/DALY averted 
<1×Uganda per capita 
GDP) 
0.0% 0.0% 61 (-487 to 666) 2018 2022 
1.5% 1.5% 80 (-491 to 723) 2018 2022 
3.0% 3.0% 100 (-499 to 786) 2018 2022 
6.0% 6.0% 143 (-513 to 901) 2018 2023 
3.0% 1.5% 87 (-432 to 683) 2018 2022 
6.0% 1.5% 128 (-649 to 1012) 2018 2022 
 216 
Table 1: Effect of choice of cost and DALY discount rates on intervention cost-effectiveness 217 
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 218 
Compared to a scenario where Uganda did not adopt the CD4 500 cells/µl threshold, adopting the 219 
threshold led to a 9.7% (90% plausible range: 4.3%-15.0%) reduction in incidence in 2030 (Figure 1g). 220 
Much of the reduction in incidence occurred during the first 4 years after the change in guidelines, 221 
with a 5.9% (3.5%-9.7%) reduction in incidence by the end of 2017. Adopting the threshold led to a 222 
gradual reduction in the HIV mortality rate over time (compared to the scenario where the change in 223 
threshold was not adopted), up to a maximum of 9.1% (3.4%-14%) in 2030 (Figure 1h). 224 
 225 
Discussion  226 
Model results suggest that the change in ART eligibility criteria made by Uganda in 2014 - increasing 227 
the CD4 threshold to 500 cells/µl - is highly unlikely to have been cost-effective during the first few 228 
years following the change in guidelines, with an estimated cost per DALY averted of $2715 (90% 229 
plausible range: +$219 to +$15,106) in 2014. Cost-effectiveness will increase over time however, and 230 
by 2030 we estimate that the change in guidelines will have had an overall cost of $100 per DALY 231 
averted (-$365 to +$593). The increase in cost-effectiveness over time occurred both through 232 
increases in the rate at which DALYs were averted, and falls in the cost of the intervention over time. 233 
Our study highlights the critical importance to the results of mathematical modelling studies of two 234 
key types of assumptions or choice. The first is time horizon over which interventions are simulated. 235 
Using WHO thresholds for cost-effectiveness, with time horizons of six years of less, six to nine years, 236 
and ten or more years, the intervention we consider here would be deemed not cost-effective, cost-237 
effective, and highly cost-effective respectively. This reflects the fact that the costs of the 238 
intervention are initially high, before falling in later years, while the number of DALYs averted each 239 
year increases over time. The choice of time horizon is likely to be similarly important when 240 
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evaluating the costs and effects of most HIV interventions or programmes, due to the long durations 241 
of HIV infections, and increasing morbidity and mortality with increasing time since infection.   242 
The second is assumptions made during model development and parameterisation. In this study, we 243 
comprehensively incorporate large amounts of the uncertainty that exists in model inputs and fitted 244 
outputs, by calibrating the model using history matching with model emulation. Additional 245 
uncertainty in costs and disability weights was also incorporated during the analysis of the model 246 
output. Providing realistic estimates of uncertainty is vital to allow policy makers to make informed 247 
decisions. It is often neglected in mathematical modelling studies however, which frequently provide 248 
only point estimates, or the results of limited sensitivity analyses. This study shows that when 249 
uncertainty in current conditions is comprehensively incorporated, the uncertainty in results can be 250 
very large. Based on our analysis, the 90% plausible range in 2030 for number of DALYS averted by 251 
the change in CD4 threshold was 118 to 503 thousand, for total cost -$89,526 to +$196 million, and 252 
for cost per DALY averted was -$499 to +$785. 253 
A limitation of our study is that we do not incorporate any changes to ART policy, coverage of male 254 
circumcision or other interventions, or changes in population sexual behaviour, that occur in Uganda 255 
after 2015. If changes occur that result in a lower incidence of HIV infection, then our results are 256 
likely to overestimate the costs, DALYs averted, and cost-effectiveness of the intervention. If 257 
changes result in a higher HIV incidence, then the cost, effects, and cost-effectiveness of the 258 
intervention are likely to be underestimated. Changes to HIV care policy and/or implementation, or 259 
the effectiveness of ART (e.g. improved regimens or increased drug resistance) will have more 260 
variable and unpredictable effects on the costs, benefits, and cost-effectiveness of the change in 261 
policy. 262 
Conclusions 263 
 264 
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Our model results suggest that the 2014 change in CD4 threshold in Uganda from 350 cells/µl to 500 265 
cells/µl is unlikely to have been cost-effective to date, but is likely to be highly cost-effective by 266 
2030. When projecting intervention effects, both the choice of time horizon and a comprehensive 267 
approach to incorporating uncertainty can have a large effect on results and conclusions. 268 
References 269 
1. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: 270 
guidelines for a public health approach: executive summary. 2002. 271 
2. World Health Organization. Consolidated guidelines on general HIV care and the use of 272 
antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health 273 
approach. 2013. 274 
3. World Health Organization. Guideline on when to start antiretroviral therapy and on pre-275 
exposure prophylaxis for HIV. 2015. 276 
4. Uganda Ministry of Health. Uganda National Antiretroviral Treatment and Care Guidelines 277 
for Adults and Children. Kampala, Uganda: 2003. 278 
5. Uganda Ministry of Health. Addendum To The Antiretroviral Treatment Guidelines For 279 
Uganda. Kampala, Uganda: 2013. 280 
6. Alistar SS, Grant PM, Bendavid E. Comparative effectiveness and cost-effectiveness of 281 
antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa. BMC 282 
medicine. 2014;12(1):1. 283 
7. Granich R, Kahn JG, Bennett R, Holmes CB, Garg N, Serenata C, et al. Expanding ART for 284 
treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050. 285 
PLoS One. 2012;7(2):e30216. 286 
8. Hontelez JA, De Vlas SJ, Tanser F, Bakker R, Bärnighausen T, Newell M-L, et al. The impact of 287 
the new WHO antiretroviral treatment guidelines on HIV epidemic dynamics and cost in South 288 
Africa. PloS one. 2011;6(7):e21919. 289 
9. Braithwaite RS, Nucifora KA, Toohey C, Kessler J, Uhler LM, Mentor SM, et al. How do 290 
different eligibility guidelines for antiretroviral therapy affect the cost–effectiveness of routine viral 291 
load testing in sub-Saharan Africa? AIDS (London, England). 2014;28(0 1):S73. 292 
10. Ishikawa N, Shimbo T, Miyano S, Sikazwe I, Mwango A, Ghidinelli MN, et al. Health outcomes 293 
and cost impact of the new WHO 2013 guidelines on prevention of mother-to-child transmission of 294 
HIV in Zambia. PloS one. 2014;9(3):e90991. 295 
11. McCreesh N, Andrianakis I, Nsubuga R, Strong M, Vernon I, McKinley T, et al. Universal, test, 296 
treat, and keep: improving ART retention is key in cost-effective HIV care and control in Uganda. 297 
BMC Infectious Diseases. 2017;17(1). 298 
12. STD/AIDS Control Programme MoH. Status of Antiretroviral Therapy Services in Uganda: 299 
Semi-Annual ART Report for January – June 2014. Kampala, Uganda: 2014. 300 
13. STD/AIDS Control Programme MoH. Status of Antiretroviral Therapy Service Delivery in 301 
Uganda Quarterly Report for March – June 2010. Kampala, Uganda: 2010. 302 
14. STD/AIDS Control Programme MoH. Status of Antiretroviral Therapy Service Delivery in 303 
Uganda Quarterly Report for July – September 2010. Kampala, Uganda: 2010. 304 
15. Uganda AIDS Commission. HIV and AIDS Uganda Country progress report; 2014. Kampala: 305 
Uganda AIDS Commission. 2015. 306 
16. Kranzer K, Lewis JJ, Ford N, Zeinecker J, Orrell C, Lawn SD, et al. Treatment interruption in a 307 
primary care antiretroviral therapy programme in South Africa: cohort analysis of trends and risk 308 
factors. Journal of acquired immune deficiency syndromes (1999). 2010;55(3):e17. 309 
14 
 
17. Uganda Ministry of Health and ICF International. 2011 Uganda AIDS Indicator Survey: Key 310 
Findings. Calverton, Maryland, USA: MOH and ICF International: 2012. 311 
18. DeSA U. World population prospects: The 2012 revision. Population Division of the 312 
Department of Economic and Social Affairs of the United Nations Secretariat, New York. 2013. 313 
19. Kaleebu P, Kamali A, Seeley J, Elliott A, Katongole‐Mbidde E. The Medical Research Council 314 
(UK)/Uganda Virus Research Institute Uganda Research Unit on AIDS–‘25 years of research through 315 
partnerships’. Tropical Medicine & International Health. 2014. 316 
20. McCreesh N, O'Brien K, Nsubuga RN, Shafer LA, Bakker R, Seeley J, et al. Exploring the 317 
potential impact of a reduction in partnership concurrency on HIV incidence in rural Uganda: A 318 
modeling study. Sexually Transmitted Diseases. 2012;39(6):407-13 319 
10.1097/OLQ.0b013e318254c84a. 320 
21. Asiki G, Murphy G, Nakiyingi-Miiro J, Seeley J, Nsubuga RN, Karabarinde A, et al. The general 321 
population cohort in rural south-western Uganda: a platform for communicable and non-322 
communicable disease studies. International journal of epidemiology. 2013:dys234. 323 
22. Andrianakis I, Vernon IR, McCreesh N, McKinley TJ, Oakley JE, Nsubuga RN, et al. Bayesian 324 
history matching of complex infectious disease models using emulation: a tutorial and a case study 325 
on HIV in Uganda. PLOS Comput Biol. 2015;11(1):e1003968. 326 
23. Andrianakis I, Vernon I, McCreesh N, McKinley TJ, Oakley JE, Nsubuga R, et al. Efficient 327 
history matching of a high dimensional individual based HIV transmission model. Journal on 328 
Uncertainty Quantification. in press. 329 
24. McCreesh N, Andrianakis I, Nsubuga RN, Strong M, Vernon I, McKinley TJ, et al. Improving 330 
ART programme retention and viral suppression are key to maximising impact of treatment as 331 
prevention–a modelling study. BMC infectious diseases. 2017;17(1):557. 332 
25. Andrianakis I, Vernon I, McCreesh N, McKinley TJ, Oakley JE, Nsubuga R, et al. History 333 
matching of a high dimensional HIV transmission individual based model. Annals of applied statistics. 334 
in review. 335 
26. Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, et al. Common values in 336 
assessing health outcomes from disease and injury: disability weights measurement study for the 337 
Global Burden of Disease Study 2010. The Lancet. 2013;380(9859):2129-43. 338 
27. Mermin J, Were W, Ekwaru JP, Moore D, Downing R, Behumbiize P, et al. Mortality in HIV-339 
infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected 340 
children: a prospective cohort study. The Lancet. 2008;371(9614):752-9. 341 
 342 
  343 
15 
 
Supporting information 344 
S1 Appendix. Technical model description 345 
S2 Appendix. Model and data description 346 
 347 
l0%
5%
10%
15%
20%
1970 1985 2000 2015
a) HIV prevalence data (overall)
l l
l
l
l
0%
20%
40%
60%
2003 2006 2009 2012 2015
d) Proportion of HIV+ on ART
l
l
0%
2%
4%
6%
8%
2003 2006 2009 2012 2015
g) Proportion on 2nd line ART
l
l
0%
5%
10%
15%
20%
1970 1985 2000 2015
b) HIV prevalence data (male)
l
l
l
l
l
0%
25%
50%
75%
100%
2003 2006 2009 2012 2015
e) Proportion starting ART with CD4<250 cells/µl
0.0
0.1
0.2
0.3
0.4
Dropout M Dropout F Restart M Restart F
h) ART dropout/restart rates (per year)
l
l
0%
5%
10%
15%
20%
1970 1985 2000 2015
c) HIV prevalence data (female)
l
l
40%
50%
60%
70%
80%
2003 2006 2009 2012 2015
f) Proportion starting ART who are female
ll
0%
25%
50%
75%
100%
2004
Male
2004
Female
2006
Male
2006
Female
2011
Male
HIV+
2011
Female
HIV+
2011
Male
HIV−
2011
Female
HIV−
i) Proportion of people ever tested for HIV
Figure 1 Click here to download Figure Figure 1.pdf 
Figure 2 Click here to download Figure Figure 2.pdf 
0.25
0.50
0.75
1.00
1 x Uganda's per capita GDP
3 x Uganda's per capita GDP
0
500
1000
1500
2000
2500
2015 2020 2025 2030
Time horizon
W
ill
in
gn
es
s 
to
 p
ay
 p
er
 D
A
LY
 a
v
er
te
d 
(U
SD
)
0.00
0.25
0.50
0.75
1.00
Proportion of parameter
sets for which intervention
is cost−effective
(net benefit>0)
Figure 3 Click here to download Figure Figure 3.pdf 
